Roches's current 56% portion of DNA is worth about 48bn… Of course, their rights to DNA drugs in ROW are a big part of the rest of Roche's value—their own product portfolio can't be worth a whole lot
This slide from Roche’s 4Q08 CC is on-point:
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
AI
